ANO5-muscular dystrophy: Clinical, pathological and molecular findings

European Journal of Neurology

Volumn 20, Issue 10, 2013, Pages 1383-1389

  Liewluck, T ^a,d   Winder, T L ^b   Dimberg, E L ^c   Crum, B A ^a   Heppelmann, C J ^a   Wang, Y ^b   Bergen, H R ^a   Milone, M ^a  

^a MAYO CLINIC   (United States)

^b Prevention Genetics   (United States)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

amyloid; ANO5; Anoctamin 5; Arrhythmia; Cardiomyopathy; Electrical myotonia

Indexed keywords

AMYLOID PROTEIN; ANOCTAMIN 5; CHLORIDE CHANNEL; UNCLASSIFIED DRUG;

ADULT; AMYLOIDOSIS; ARTICLE; CLINICAL ARTICLE; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN TISSUE; HYPOKINESIA; LASER CAPTURE MICRODISSECTION; MALE; MASS SPECTROMETRY; MUSCLE BIOPSY; MUSCULAR DYSTROPHY; MYOTONIA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; SKELETAL MUSCLE; SUPRAVENTRICULAR TACHYCARDIA;

AMYLOID; ANO5; ANOCTAMIN-5; ARRHYTHMIA; CARDIOMYOPATHY; ELECTRICAL MYOTONIA;

ADULT; AGED; AMYLOIDOSIS; CHLORIDE CHANNELS; FEMALE; GENOTYPE; HUMANS; LASER CAPTURE MICRODISSECTION; MALE; MIDDLE AGED; MUSCLE, SKELETAL; MUSCULAR DYSTROPHIES; MUTATION; MYOCARDIUM; PHENOTYPE;

EID: 84883797005     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12191     Document Type: Article

References (19)

1. Bolduc V, Marlow G, Boycott KM, et al. Recessive mutations in the putative calcium-activated chloride channel Anoctamin 5 cause proximal LGMD2L and distal MMD3 muscular dystrophies. Am J Hum Genet 2010; 86: 213-221.
2. Duran C, Qu Z, Osunkoya AO, et al. ANOs 3-7 in the anoctamin/Tmem16 Cl- channel family are intracellular proteins. Am J Physiol Cell Physiol 2012; 302: C482-C493.
3. Wahbi K, Behin A, Becane HM, et al. Dilated cardiomyopathy in patients with mutations in anoctamin 5. Int J Cardiol 2012; pii: S0167-5273(12)01176-X. [Epub ahead of print].
4. Hicks D, Sarkozy A, Muelas N, et al. A founder mutation in Anoctamin 5 is a major cause of limb-girdle muscular dystrophy. Brain 2011; 134: 171-182.
5. Penttila S, Palmio J, Suominen T, et al. Eight new mutations and the expanding phenotype variability in muscular dystrophy caused by ANO5. Neurology 2012; 78: 897-903.
6. Mahjneh I, Jaiswal J, Lamminen A, et al. A new distal myopathy with mutation in anoctamin 5. Neuromuscul Disord 2010; 20: 791-795.
7. Milone M, Liewluck T, Winder TL, et al. Amyloidosis and exercise intolerance in ANO5 muscular dystrophy. Neuromuscul Disord 2012; 22: 13-15.
8. Bouquet F, Cossee M, Behin A, et al. Miyoshi-like distal myopathy with mutations in anoctamin 5 gene. Rev Neurol (Paris) 2012; 168: 135-141.
9. Schessl J, Kress W, Schoser B. Novel ANO5 mutations causing hyper-CK-emia, limb girdle muscular weakness and Miyoshi type of muscular dystrophy. Muscle Nerve 2012; 45: 740-742.
10. Penisson-Besnier I, Saint-Andre JP, Hicks D, et al. Myopathy caused by anoctamin 5 mutations and necrotizing vasculitis. J Neurol 2012; 259: 1988-1990.
11. Magri F, Bo RD, D'Angelo MG, et al. Frequency and characterisation of anoctamin 5 mutations in a cohort of Italian limb-girdle muscular dystrophy patients. Neuromuscul Disord 2012; 22: 934-943.
12. Amato AA, Brown RH Jr. Dysferlinopathies. Handb Clin Neurol 2011; 101: 111-118.
13. Spuler S, Carl M, Zabojszcza J, et al. Dysferlin-deficient muscular dystrophy features amyloidosis. Ann Neurol 2008; 63: 323-328.
14. Rosales XQ, Gastier-Foster JM, Lewis S, et al. Novel diagnostic features of dysferlinopathies. Muscle Nerve 2010; 42: 14-21.
15. Klein CJ, Vrana JA, Theis JD, et al. Mass spectrometric-based proteomic analysis of amyloid neuropathy type in nerve tissue. Arch Neurol 2011; 68: 195-199.
16. Vrana JA, Gamez JD, Madden BJ, et al. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood 2009; 114: 4957-4959.
17. Milone M, McEvoy KM, Sorenson EJ, Daube JR. Myotonia associated with caveolin-3 mutations. Muscle Nerve 2012; 45: 897-900.
18. Gertz MA, Dispenzieri A. Immunoglobulin light-chain amyloidosis: growing recognition, new approaches to therapy, active clinical trials. Oncology (Williston Park) 2012; 26: 152-161.
19. Plante-Bordeneuve V, Said G. Familial amyloid polyneuropathy. Lancet Neurol 2011; 10: 1086-1097.